Supply Chain and Logistics for Cell and Gene Therapies Summit on June 09-11, 2026 in Washington, United States

In 2025, cell and gene therapy reached a pivotal moment. Amid rising tariffs, shifting regulations, and capacity constraints, the industry gained clarity on what it takes to scale successfully. As a result, the focus on scaling novel therapies safely and efficiently has never been stronger, introducing a new era of operational excellence and expanded patient access.

As we enter 2026, AI, digitalization, and IoT are transforming how cell and gene therapies are planned, tracked, and delivered end-to-end. With smarter, data-driven decision-making, supply chain teams can better navigate tariff fluctuations, manufacturing variability, and regulatory complexity.

Designed by and for supply chain leaders across biopharma, including Roche, Bristol Myers Squibb, Johnson and Johnson, Genentech, ProKidney, and Vyriad the 7th Supply Chain and Logistics for Cell and Gene Therapy Summit delivers best-in-class perspectives on global patient supply, cost of goods optimization, and accelerating clinical and commercial programs through digital innovation. With strong end-to-end focus, the agenda reflects the real challenges facing advanced therapy supply chains today.

If you are a supply chain leader in cell and gene therapy, this is your must-attend opportunity to connect with peers, benchmark best practices, and gain actionable insights to build a resilient, future-ready supply chain that delivers therapies to patients, reliably and at scale.

URLs:

Tickets: https://go.evvnt.com/3498265-2?pid=10008

Brochure: https://go.evvnt.com/3498265-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Drug developer Pricing - 3 Day Pass: USD 4397.00,

Drug Developer Pricing - Conference Only: USD 3099.00,

Academic Pricing - 3 Day Pass: USD 3797.00,

Academic Pricing - Conference Only: USD 2699.00,

Service Provider Pricing - 3 Day Pass: USD 5297.00,

Service Provider Pricing - Conference Only: USD 3799.00

Speakers: Albert Ribickas, Manager, Bloody and Marrow Transplant Laboratory, Clinical Trial and Commercial Product Handling Team, Moffitt Cancer Center, Robin White, Deputy Technical Director, ICCBBA, Karen Moniz, Director - Technical, ICCBBA, Luke Russell, Executive Vice President, Vyriad, Sheri Winkels, Senior Director of Quality and Compliance, Vyriad, Tuo Wang, Associate Director, Supply Chain Category Management, Sana Biotechnology, Patrick Johnson, Director - Supply Chain Patient Experience, ProKidney, Sherry Kallingal, Senior Director - Operational Excellence, ProKidney, James Carr, Director - US Supply Chain and Procurement, Legend Biotech, Rachel Rubiano, Manager, Clinical Operations and Logistics, Kite Pharma Inc, Afua Achampong-Duku, Senior Manager, Procurement, Immatics Gmbh, Patrick Gailliot, Senior Director - Patient Operations, Abeona Therapeutics, Gustavo Stanev Francisco, Supply Chain Manager - Cell and Gene Therapy, Roche, Lizette Caballero, Associate Director - Clinical Cell Therapy Liaison, Johnson and Johnson, Marcos Palacio, Logistics Integrator Lead - Advanced Therapies, Johnson and Johnson, Julia Batycky, Cell and Gene Therapy, Patient Operations Manager, Genentech, Irena Maksimovic, Senior Director - Strategy, Business Operations and Clinical Supply Chain, Bristol Myers Squibb, Oscar Monroy, Senior Manager - Supply Chain Process Management, Bristol Myers Squibb, Arthur Wang, Associate Director - Supply Chain Planning, AstraZeneca